Cost-effectiveness sequential modeling of ranibizumab versus usual care in age-related macular degeneration

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 246, Issue 11, 2008, Pages 1527-1534

  Cohen, S Y ^a   Bremond Gignac, Dominique ^b   Quentel, G ^a   Mimoun, G ^c   Citterio, T ^d   Bisot Locard, S ^d   Beresniak, A ^e,f  

^a Centre Ophtalmologique d'Imagerie et de Laser   (France)

^b HÔPITAL ROBERT DEBRÉ   (France)

^c UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^d Novartis Groupe France SA   (France)

^e et Institut de recherche et documentation en économie de la santé   (France)

^f DATA MINING INTERNATIONAL   (Switzerland)

Author keywords

Age related macular degeneration; Cost effectiveness; Modelling; Ranibizumab

Indexed keywords

PEGAPTANIB; RANIBIZUMAB; VERTEPORFIN;

ARTICLE; BLINDNESS; CLINICAL PRACTICE; COMPUTER SIMULATION; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FRANCE; HUMAN; INTERMETHOD COMPARISON; LOW LEVEL LASER THERAPY; PATIENT CARE; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RISK REDUCTION; SCORING SYSTEM; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ACUITY;

ANTIBODIES, MONOCLONAL; APTAMERS, NUCLEOTIDE; BLINDNESS; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DECISION TREES; DRUG THERAPY, COMBINATION; HUMANS; LASER THERAPY; MACULAR DEGENERATION; MODELS, ECONOMIC; PHOTOSENSITIZING AGENTS; POPULATION SURVEILLANCE; PORPHYRINS; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 54049113783     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-008-0890-8     Document Type: Article

References (28)

1. Chaine G, Rohart C (2007) Epidemiology and risk factors for age-related macular degeneration. J Fr Ophtalmol 30:74
2. Ambati J, Ambati B, Yoo S, Ianchulev S, Adamis A (2003) Age-related macular degeneration: Etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol 48:257-293
3. Ferris FL, Fine SL, Hyman L (1984) Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 102(11):1640-1642 Nov
4. Pina JP, Offret H, Labetoulle M (2007) Les nouveaux traitements de la DMLA. Medecine 3(10):443-445
5. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group (1999) Photodynamic therapy of subfoveal choroidal neovascularisation in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report. Arch Ophthalmol 117:1329-1345
6. Rosenfeld PJ, Heier JS, Hantsbatger G, Shams N (2006) Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology 113:632
7. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, for the Marina Study Group (2006) Ranibizumab for neovascular age-related macular degeneration. New Eng J Med 355:1419-1431
8. Bradley J, Ju M, Robinson GS (2007) Combination therapy for the treatment of ocular neovascularization. Angiogenesis 10:141-148
9. Rajczi A (2007) A critique of the innovation argument against a national health program. Bioethics 21(6):316-323 Jul
10. Weinstein MC (2006) Recent developments in decision-analytic modelling for economic evaluation. Pharmacoeconomics 24(11):1043-1053
11. Polsky D, Glick HA, Wilke R, Schulman K (1997) Confidence Intervals for cost-effectiveness ratios: A comparison of four methods. Health Econ 6:243-252
12. Kegan B, West RW (2005) Modeling the simple epidemic with deterministic differential equations and random initial conditions. Math Biosci 195(2):179-193
13. Takeda AL, Colquitt JL, Clegg AJ, Jones J (2007) Pegaptanib and ranibizumab for neovascular age-related macular degeneration: A systematic review. Br J Ophthalmol 91(9):1177-1182
14. Rosenfeld PJ, Rich RM, Lalwani GA (2006) Ranibizumab: Phase III clinical trial results. Ophthalmol Clin North Am 19:361-372
15. Heier JS, Antoszyk AN, Pavan PR, Leff SR, Rosenfeld PJ, Ciulla TA, Dreyer RF, Gentile RC, Sy JP, Hantsbarger G, Shams N (2006) Ranibizumab for treatment of neovascular age-related macular degeneration: A phase I/ II multicenter, controlled, multidose study. Ophthalmology 113(4):642.e1-4. Epub 2006 Feb 14.
16. Kaiser PK, Blodi BA, Shapiro H, Acharya NR, MARINA Study Group (2007) Angiographic and Optical Coherence Tomographic Results of the MARINA Study of Ranibizumab in Neovascular Age-Related Macular Degeneration. Ophthalmology 11
17. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial GroupD - Amico DJ, Masonson HN, Patel M, Adamis AP, Cunningham ET Jr, Guyer DR, Katz B (2006) Pegaptanib sodium for neovascular age-related macular degeneration: Two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 113(6):992-1001
18. Cunningham ET Jr, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D'Amico DJ, Goldbaum M, Guyer DR, Katz B, Patel M, Schwartz SD (2005) Macugen Diabetic Retinopathy Study Group. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 112(10):1747-1757
19. Macugen AMD Study Group (2007) Pegaptanib 1-Year Systemic Safety Results from a Safety-Pharmacokinetic Trial in Patients with Neovascular Age-Related Macular Degeneration. Ophthalmology 114(9):1702-1712
20. Schmidt-Erfurth U (1998) Photodynamic therapy. Minimally invasive treatment of choroidal neovascularisation. Ophthalmology 95:725-731
21. Kaiser PK (2006) Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open label extension. Graefe Arch Clin Exp Ophthalmol 244:1132-1142
22. Liggett PE, Colina J, Chaudhry NA, Tom D, Haffner G (2006) Triple therapy of intravitreal triamcinolone, photodynamic therapy, and pegaptanib sodium for choroidal neovascularization. Am J Ophthalmol 142(6):1072-1074
23. Brown MM, Brown GC, Stein JD, Roth Z, Campanella J, Beauchamp GR (2005) Age-related macular degeneration: Economic burden and value-based medicine analysis. Can J Ophthalmol 40(3):277-287
24. Brown GC, Brown MM, Brown H, Godshalk AN (2007) Pharmacoeconomics and macular degeneration. Curr Opin Ophthalmol 18(3):206-211
25. Raftery J, Clegg A, Jones J, Tan SC, Lotery A (2007) Ranibizumab (lucentis) versus bevacizumab (avastin): Modelling cost effectiveness. Br J Ophthalmol 91(9):1244-1246
26. Duru G, Auray JP, Beresniak A, Lamure M, Paine A, Nicoloyannis N (2002) Limitations of the methods used for calculating quality-adjusted life years values. Pharmacoeconomics 20(7):463-473
27. McGregor M, Caro JJ (2006) QALYs: Are they helpful to decision-makers? Pharmacoeconomics 24(10):947-952
28. Bremond-Gignac D, Tixier J, Missotten T, Laroche L, Beresniak A (2002) Evaluation of the quality of life in ophthalmology. Presse Med 19;31(34):1607-1612